Abstract. Clock genes are expressed in a self-perpetuating, circadian pattern in virtually every tissue including the human gastrointestinal tract. They coordinate cellular processes critical for tumor development, including cell proliferation, DNA damage response and apoptosis. Circadian rhythm disturbances have been associated with an increased risk for colon cancer and other cancers. This mechanism has not been elucidated, yet may involve dysregulation of the ‘period’ (PER) clock genes, which have tumor suppressor properties. A variable number tandem repeat (VNTR) in the PERIOD3 (PER3) gene has been associated with sleep disorders, differences in diurnal hormone secretion, and increased premenopausal breast cancer risk. Susceptibility related to PER3 has not been examined in conjunction with adenomatous polyps. This exploratory case-control study was the first to test the hypothesis that the 5-repeat PER3 VNTR sequence is associated with increased odds of adenoma formation. Information on demographics, medical history, occupation and lifestyle was collected prior to colonoscopy. Cases (n=49) were individuals with at least one histopathologically confirmed adenoma. Controls (n=97) included patients with normal findings or hyperplastic polyps not requiring enhanced surveillance. Unconditional multiple logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs), after adjusting for potential confounding. Adenomas were detected in 34% of participants. Cases were more likely to possess the 5-repeat PER3 genotype relative to controls (4/5 OR, 2.1; 95% CI, 0.9-4.8; 5/5 OR, 5.1; 95% CI, 1.4-18.1; 4/5+5/5 OR, 2.5; 95% CI, 1.7-5.4). Examination of the Oncomine microarray database indicated lower PERIOD gene expression in adenomas relative to adjacent normal tissue. Results suggest a need for follow-up in a larger sample.

Introduction

According to recent estimates, over 136,000 new patients and more than 50,000 deaths occurred in 2014 in the USA due to colorectal cancer (CRC), which makes it the third most common and deadly cancer among both men and women (1). Colorectal adenomatous polyps are the primary precursor lesions for CRC, accounting for 85-90% of cases (2). Developing a better understanding of factors related to adenoma susceptibility and progression thus represents an important goal for CRC prevention.

Disruption of circadian rhythms or clock gene expression is emerging as a novel and potentially modifiable cancer risk factor, although the pathophysiological mechanism is incompletely understood (3,4). The central circadian pacemaker is located in the suprachiasmatic nuclei (SCN) of the anterior hypothalamus. Generation of circadian rhythms is accomplished primarily via photic input from the retina, which synchronizes the reciprocal transcriptional-translational
expression of at least nine core clock genes: PER1, PER2, PER3, CRY1, CRY2, CLOCK, BMAL1, TIM and CK1ε (3-5).

In most tissues, this system facilitates the diurnal expression of ~10% of the entire mammalian genome via genetic and epigenetic regulation of clock-controlled genes (6-10). Various factors, such as shift work, late bedtimes or poorly timed light exposure can disrupt endogenous circadian timing, thus altering clock gene expression and the cellular processes they help regulate (4). Since clock genes regulate processes that are considered hallmarks of carcinogenesis (cell cycle control, DNA damage response, apoptosis), their dysregulation may serve as an underlying biological mechanism linking altered circadian rhythms with cancer (4,11-15). Clock gene polymorphisms have been associated with non-Hodgkin's lymphoma and cancers of the breast and prostate (4). Clock gene polymorphic variation also influences sleep regulation (5,16,17), which may contribute to increases in cancer susceptibility that have been observed among people who experience circadian rhythm disturbances or sleep disruption (18-21). For example, shift work and sleep disturbances have been associated with increased CRC risk (20,22-24) and truncated sleep (<6 h/night) has been associated with an increased odds of colorectal adenoma formation relative to adenoma-free controls (18).

The period (PER) clock genes have immunomodulatory (5,25,26) and tumor suppressor properties (4,11,19,27,28). Mutation or altered expression of PER genes has been observed among cancer patients relative to controls, within human tumors relative to adjacent normal tissue and in experimental cancer bioassays (4,11,27,29-36). Whether differential expression of PER or other clock genes occurs in human adenomas versus normal tissue is not known. The PER3 variable number tandem repeat (VNTR; rs57875989) length polymorphism contains 4 or 5 copies of a 54-bp sequence encoding 18 amino acids. The 5-repeat variant adds several potential phosphorylation motifs to the gene, and PER3’s interaction with circadian processes may be enhanced among those individuals (16,37). The 5-repeat PER3 allele is associated with a relatively penetrant phenotype that includes morning circadian preference (16,38,39), increased cognitive decline in response to sleep deprivation (16), differences in levels or timing of melatonin or cortisol secretion (37,40,41), and a tendency towards depressive symptoms or an earlier onset of bipolar disorder (42,43). PER3 is considered a candidate tumor suppressor gene (27,28,33), and the 5/5 PER3 VNTR genotype has been associated with increased premenopausal breast cancer risk (33), though not consistently (21,44).

Recently, the relationship between the PER3 VNTR and CRC risk was examined in Greece and no association was observed, though a relatively small portion of the study population was included (45). The role of PER3 or other clock genes in human adenoma formation has yet to be examined in detail. Therefore, this exploratory study tested the hypothesis that adenoma cases are hetero- or homozygous for the 5-repeat PER3 variant relative to adenoma-free controls.

Materials and methods

Participants and data from two different endoscopy centers in the Columbia, SC metropolitan area were pooled for this analysis; the South Carolina Medical Endoscopy Center (Site 1, n=93), and the WJB Dorn Veterans Administration Medical Center (DVAMC; Site 2, n=53). Eligible patients were English literate adults 30-80 years who were scheduled for a screening or surveillance colonoscopy at either site. The present study was approved by the Institutional Review Boards (IRB) of the DVAMC and the University of South Carolina prior to informed consent and enrollment. Participants provided a peripheral blood sample for DNA recovery and completed a questionnaire to ascertain information on: demographic (gender, marital status, income, race, ethnicity), lifestyle (smoking history, diet, physical activity), and occupational (employment status, job industry, type of shift, history of shift work) factors, as well as personal and family history of cancer and other chronic diseases. Individuals who were getting a colonoscopy due to symptoms (presence of gastrointestinal bleeding, hematochezia, melena, fecal occult blood, iron deficiency or constipation) were collapsed into the screening category due to low counts (n=10). Cases were defined as individuals with at least one histologically confirmed adenoma, and controls were subjects with a normal colonoscopy or a normal biopsy not requiring heightened surveillance (e.g., hyperplastic polyp).

Genomic DNA was extracted and genotyping for the PER3 VNTR sequence was performed using previously described methods (42,46). For participants recruited from Site 1, the PER3 VNTR sequence was amplified via polymerase chain reaction (PCR) using the following forward (5'-TGGCAGTGAGCACGTCCT-3’) and reverse (5'-AGTGGCAGTAGGATGGGATG-3’) primers (33,44). The final 20 µl PCR reaction mixture was made up of 1 µl (20 ng) of genomic DNA, 10 µl of OneTaq® Hot Start 2X Master Mix with standard buffer (20 mM Tris-Cl, 22 mM KCl, 22 mM NaCl, 1.8 mM MgCl2, 5% glycerol, 0.05% Tween-20, 0.2 mM dNTPs, 25 U/ml OneTaq Hot Start DNA Polymerase; New England BioLabs, Inc., Ipswich, MA, USA), 1 µl (0.375 µM) of each oligonucleotide primer and 7 µl of PCR-grade water. The reactions were heated to 94°C for 2 min followed by 35 cycles at 94°C for 30 sec, 60°C for 30 sec and 72°C for 45 sec. Finally, the reactions were extended for 7 min at 72°C using the S1000 Thermal Cycler (Bio-Rad, Hercules, CA, USA). PCR products were then separated by electrophoresis on a 3% agarose gel. For Site 2, after DNA extraction, 200 ng of genomic DNA was subjected to PCR. The PCR primers used for Site 2 assays were: 5’-CAGAAAATTTATGACACTACAGAATGTG-3’ (forward) and 5’-AACCTTGCACTTGTGCACTC-3’ (reverse). The resulting reaction mixture consisted of 25 µl standard PCR buffer, 5% DMSO, 1.0 mM MgCl2, 0.2 mM dNTP, 1 U Taq polymerase (Gibco-Invitrogen, Carlsbad, CA, USA), and 0.4 µM of each oligonucleotide primer. PCR cycling conditions were as follows: 3 min at 94°C, 35 cycles of 30 sec at 94°C, 30 sec at 58°C and 30 sec at 72°C; and at 72°C for 30 sec. PCR products were extended using a Perkin-Elmer GeneAmp System 9700 (Waltham, MA, USA). A 2% agarose gel stained with ethidium bromide was used to separate and visualize the PCR fragments at 220 V for 30 min. Both primers provide valid characterization of the PER3 VNTR (33,42,44-48). DNA sequences of amplicons produced by each set of primers were verified via Sanger sequencing. Duplicate genotyping was performed in
Table I. Demographic characteristics of study population.

| Variable                               | Total population (n=146) | Controls (n=97) | Cases (n=49) | Cases vs. controls P-value^b |
|----------------------------------------|--------------------------|----------------|--------------|-----------------------------|
|                                        | n (%)                    | n (%)          | n (%)        |                             |
| Sex                                    |                          |                |              |                             |
| Male                                   | 105 (72)                 | 67 (70)        | 38 (78)      |                             |
| Female                                 | 40 (28)                  | 39 (30)        | 11 (22)      |                             |
| Race                                    |                          |                |              |                             |
| European American                      | 94 (65)                  | 58 (60)        | 36 (73)      |                             |
| African American                       | 51 (35)                  | 38 (40)        | 13 (27)      |                             |
| Marital status                         |                          |                |              |                             |
| Unmarried                               | 38 (26)                  | 27 (28)        | 11 (22)      |                             |
| Married                                 | 107 (74)                 | 69 (72)        | 38 (78)      |                             |
| Education                               |                          |                |              |                             |
| Up to High School                      | 52 (36)                  | 34 (35)        | 18 (37)      |                             |
| Some College                           | 40 (28)                  | 25 (26)        | 15 (31)      |                             |
| College Undergraduate or Post-Graduate Degree | 53 (37) | 37 (39) | 16 (33) |                             |
| Income level                           |                          |                |              |                             |
| Under $50,000                          | 63 (46)                  | 40 (45)        | 23 (49)      |                             |
| ≥$50,000 to $100,000                   | 53 (39)                  | 38 (43)        | 15 (32)      |                             |
| >$100,000                              | 20 (15)                  | 11 (12)        | 9 (19)       |                             |
| Body mass index (kg/m^2)               |                          |                |              |                             |
| Normal (≤25)                            | 33 (23)                  | 19 (20)        | 14 (29)      |                             |
| Overweight (>25)                       | 113 (77)                 | 78 (80)        | 35 (71)      |                             |
| Family history of colorectal cancer    |                          |                |              |                             |
| Yes                                    | 25 (17)                  | 17 (18)        | 8 (16)       |                             |
| No                                     | 120 (83)                 | 79 (82)        | 41 (84)      |                             |
| Diagnosis of diabetes                  |                          |                |              |                             |
| Yes                                    | 42 (29)                  | 24 (25)        | 18 (38)      |                             |
| No                                     | 102 (81)                 | 71 (75)        | 31 (62)      |                             |
| History of smoking                     |                          |                |              |                             |
| Ever                                   | 91 (63)                  | 53 (56)        | 38 (78)      |                             |
| Never                                  | 53 (37)                  | 42 (44)        | 11 (22)      |                             |
| Work decision latitude^d               |                          |                |              |                             |
| Often or always                        | 51 (35)                  | 28 (29)        | 23 (57)      |                             |
| Never or sometimes                     | 21 (14)                  | 18 (19)        | 3 (6)        |                             |
| Unknown                                | 74 (51)                  | 51 (53)        | 23 (47)      |                             |
| Age group (years)                      |                          |                |              |                             |
| 30-54                                  | 45 (31)                  | 34 (35)        | 11 (22)      |                             |
| 55-65                                  | 66 (46)                  | 44 (46)        | 22 (45)      |                             |
| >65                                    | 34 (23)                  | 18 (19)        | 16 (33)      |                             |
| Reason for colonoscopy                 |                          |                |              |                             |
| Screening                              | 78 (53)                  | 58 (60)        | 20 (41)      |                             |
| Surveillance                           | 68 (47)                  | 39 (40)        | 29 (59)      |                             |
| Lifetime shift work                    |                          |                |              |                             |
| (years)                                | 3 (0, 12.3)              | 5 (0, 15)      | 2 (0, 10)    |                             |

^aNumber of subjects for each variable category may not equal total number of subjects due to missing data; ^bChi-squared test for differences in proportions or Wilcoxon rank sum test for differences in medians between cases and controls; ^c'n'=3 subjects in the underweight BMI category (≤18.5 kg/m^2); ^dDefined by the question: 'Do you have a good deal of say in decisions about your work?'.
Table II. \textit{PER3} VNTR genotype by adenoma status.

| Genotype       | Controls (n=97) n (%) | Cases (n=49) n (%) | Crude OR | 95\% CI | P-value | Adjusted OR\textsuperscript{a} | 95\% CI | P-value |
|----------------|-----------------------|--------------------|----------|---------|---------|-------------------------------|---------|---------|
| 4/4            | 52 (54)               | 16 (33)            | Ref      | -       | -       | Ref                           | -       | -       |
| 4/5            | 38 (39)               | 24 (49)            | 2.1      | 0.9-4.4 | 0.06    | 2.1                           | 0.9-4.8 | 0.07    |
| 5/5            | 7 (7)                 | 9 (18)             | 4.2      | 1.3-13.0| 0.01    | 5.1                           | 1.4-18.1| 0.01    |
| 4/5 or 5/5     | 45 (46)               | 33 (67)            | 2.4      | 1.7-4.9 | 0.02    | 2.5                           | 1.7-5.4 | 0.02    |

\textsuperscript{a}Adjusted for, decision latitude at work, recruitment site, procedure reason; OR, odds ratio; CI, confidence interval; VNTR, variable number tandem repeat.

10\% of all samples from both sites for quality control purposes, and there was 100\% concordance among duplicates (42). Hardy-Weinberg equilibrium (HWE) was examined, and gene frequencies for the \textit{PER3} VNTR were in HWE among the entire study population (p=0.74), and among controls from both sites (p=0.99) or within each site (Site 1, p=0.94; Site 2, p=0.82, data not shown).

Statistical analyses were performed using the Statistical Analysis Software (SAS\textsuperscript{\textregistered}) computer program (version 9.2; SAS Institute, Cary, NC, USA) and the R meta-analysis package (version 2.14.1; http://cran.r-project.org). Potential differences between study variables by case status within the entire study population, and within each site separately, were examined using the Chi-squared test for differences between proportions. Unconditional multiple logistic regression was used to estimate odds ratios (ORs) with 95\% confidence intervals (95\% CIs) for \textit{PER3} VNTR genotype among adenoma cases relative to controls using the 4/4 genotype as referent (33,42). Co-variates considered for inclusion in adjusted models were known or suspected adenoma or CRC risk factors [age, gender, race, body mass index (BMI), CRC family history, smoking history, work-related factors, diet, vitamin and supplement use, physical activity, sociodemographic characteristics (income, education), personal medical history], recruitment site and variables that differed among participants and non-participants (gender, personal cancer history, ulcer diagnosis, lactose intolerance, secondhand smoke exposure). Final models included variables that were statistically significant (p≤0.05) in the saturated model, or produced at least a 10\% change in the parameter estimate for genotype (decision latitude at work, procedure reason, recruitment site). Differences in median shift work duration by \textit{PER3} genotype were compared using the Wilcoxon rank sum test. Ancillary analyses examined relationships between lifetime shift work and adenoma status; or \textit{PER3} genotype and adenoma status after stratification by procedure reason (screening vs. surveillance colonoscopy), or shift work (none vs. any, or median split on years of lifetime shift work). Random-effects meta-analysis was used to evaluate the study hypothesis since recruitment occurred at two separate sites. The I\textsuperscript{2} and Q statistics were used to assess heterogeneity between sites. Finally, Oncomine (49), a publicly accessible gene expression microarray database, was queried to examine potential differential expression of \textit{PER1}, \textit{PER2} and \textit{PER3} clock genes in adenomas versus adjacent normal tissue.

Results

The median age of the participants was 58 years (25-75th percentile: 53-64 years), and they were primarily European American (EA) (65\%), and male (72\%). Most (69\%) participants had engaged in at least one year of shift work (median, 3 years; 25-75th percentile: 0-12.3 years). Adenomas were detected in 34\% of participants (females, 28\%; males; 36\%). Compared to controls, cases were more likely to have smoked (78 vs. 56\%), have higher workplace decision latitude (57 vs. 29\%), and have undergone a surveillance rather than a screening colonoscopy (59 vs. 40\%, Table I). The following characteristics were different by site, regardless of case status (p≤0.05, data not shown): gender, race, marital status, income level, ever smoking, age group, reason for procedure and number of years of lifetime shift work. Compared to controls, cases in Site 1 were less likely to be diagnosed with diabetes, more likely to have smoked in the past and more likely to undergo a surveillance colonoscopy (data not shown). Site 2 cases were older compared to controls (data not shown).

Overall \textit{PER3} VNTR genotype frequencies (4/4, 47\%; 4/5, 42\%; 5/5, 11\%) were consistent with those reported previously (21,33,37-48,50). Adenoma cases were more likely than controls to possess one or two copies of the 5-repeat sequence (4/5 OR, 2.1; 95\% CI, 0.9-4.8; 5/5 OR, 5.1; 95\% CI, 1.4-18.1; 4/5+5/5 OR, 2.5; 95\% CI, 1.7-5.4, Table II). The distribution of lifetime shift work history varied by \textit{PER3} VNTR genotype (Table III). Those with the 4/4 genotype had greater median lifetime years of shift work (5 years) compared to those with the 4/5 (2 years, p=0.02), 5/5 (0.75 years, p=0.05) or the combined genotype (4/5+5/5, 1 year, p<0.01). Shift work or the combined effect of shift work and genotype was not related to adenoma case status (data not shown). When analyses were stratified by procedure reason, the 5/5 genotype was associated with adenoma status among screening patients (OR, 10.7; 95\% CI, 1.4-80.7), although CIs were wide and no statistically significant relationship was observed among those with other combinations of genotype and procedure reason (data not shown). When the data were evaluated using meta-analytic methods, adenoma cases were ~2-3 times more likely than controls to have at least one 5-repeat allele, although the CIs were wide and did not achieve statistical significance (4/5 OR, 2.27; 95\% CI, 0.43-11.62; \textit{p}_{\text{heterogeneity}}=0.12; 4/5 OR, 3.02; 95\% CI, 0.72-12.71; \textit{p}_{\text{heterogeneity}}=0.84; 4/5+5/5 OR, 60\%; 5/5 OR, 10.7; 95\% CI, 1.4-80.7), although CIs were wide and no statistically significant relationship was observed among those with other combinations of genotype and procedure reason (data not shown).
Table III. Relationship between PER3 VNTR genotype and lifetime shift work exposure.

| Lifetime shift work (years) | n (%) | 25th Percentile | 75th Percentile | P-valuea |
|-----------------------------|-------|-----------------|-----------------|----------|
| n (%)                       | Median |                 |                 |          |
| 4/4                         | 67 (47)| 5               | 15              | -        |
| 4/5                         | 61 (42)| 2               | 0               | 10       | 0.020   |
| 5/5                         | 16 (11)| 0.75            | 8.5             | 0.050    |
| 4/5 or 5/5                  | 77 (53)| 1               | 10              | 0.008    |

aWilcoxon rank sum test for group differences in median duration shift work by genotype using the 4/4 genotype as the referent (n=2 subjects with missing data on lifetime shift work). VNTR, variable number tandem repeat.

OR, 2.35; 95% CI, 0.60-9.21; χ² heterogeneity, 0.14; F, 54%, data not shown.

Data for PER1, PER2 and PER3 expression in adenomas relative to normal tissue were retrieved from the Oncomine microarray database (Table IV) (51-53). A statistically significant reduction in PER3 expression was observed in adenomas relative to normal tissue among each of the available data sets; similar differences were noted for PER1, and to a lesser extent PER2 expression (Table IV).

Discussion

Few studies have examined the role of the PER3 VNTR on cancer-related outcomes (21,33,44,45). To our knowledge, this exploratory study is the first to examine the relationship between the PER3 VNTR and human adenoma risk. Adenoma cases were ~2-5 times more likely to possess the 5-repeat PER3 length polymorphism compared to controls. Quality criteria for genotyping and colonoscopy were satisfactory (54,55), and adjustment for potential confounding by known or suspected adenoma risk factors did not alter the interpretation of the results. The meta-analysis indicated that the strength of association between PER3 genotype and adenoma status was generally consistent with the main analysis and the results were not strongly impacted by heterogeneity between the sites. Some imprecise risk estimates with wide confidence intervals were observed due to a limited sample size, particularly for the stratified analyses. Thus, examination of possible effect modification by factors such as race, chronotype or procedure indication (screening vs. surveillance) would benefit from a larger sample in future studies. Nonetheless, the lower bound of the confidence intervals suggest an increased risk for adenoma formation of at least ~40% among homozygous 5-repeat PER3 variants. PER gene expression was not performed among cases and controls in the present study, thus changes in expression relative to the PER3 VNTR genotype could not be evaluated. However, our query of the Oncomine database indicated that PER3 and to a lesser extent PER1 and PER2 expression was reduced among adenomas compared to normal mucosa, which is consistent with previous studies that observed a reduction in PER1 and PER3 expression in human colorectal tumors relative to adjacent normal tissue (32,36,56,57).

The spectrum of known genetic susceptibility markers does not fully account for all CRC cases. For example, 10 loci identified from genome-wide association studies had population attributable risks ranging from 1.7 to 11.9% (58), and another study reported that up to 35% of CRC cases are due to heritable factors (59). The present study mirrors previous investigations that have examined clock gene polymorphisms in conjunction with cancer susceptibility (4,21,33,44,45), including one that identified an association between the 5-repeat PER3 VNTR sequence and increased odds of premenopausal breast cancer (33). Evidence suggests that PER3 may function as a tumor suppressor. A recent study among PER3 knockout mice indicated that 36% of the homozygous null variants developed chemically-induced mammary tumors compared to 12% among heterozygotes and 0% among wild-type mice (27). Another recent study used methylation arrays and stringent selection criteria to screen >14,000 genes to identify putative tumor suppressors associated with human hepatocellular carcinoma; PER3 was one of only three candidate tumor suppressor genes identified (28). Chronic gastrointestinal inflammation is important for adenoma and CRC development (2), and since PERIOD genes play a role in immune system regulation, their expression may influence these processes (5,25,26). Recently, another PER3 polymorphism (rs2797685) was associated with

Table IV. PERIOD gene expression in human adenomas vs. normal tissue.

| Referent tissue | Pathological tissue type | PER1  | P-value | PER2  | P-value | PER3  | P-value | Ref. |
|-----------------|--------------------------|-------|---------|-------|---------|-------|---------|------|
| Normal colon epithelium (n=22) | Colorectal adenoma epithelium (n=56) | -1.3  | 0.003   | -1.2  | 0.050   | N/A   | N/A     | (51) |
| Normal colon (n=32) | Colon adenoma (n=25) | -1.7  | 0.008   | -1.2  | 0.003   | -2.3  | <0.001  | (52) |
| Normal colon (n=32) | Rectal adenoma (n=7) | -1.9  | 0.050   | 1.3   | 0.880   | -1.7  | 0.001   | (52) |
| Normal colon (n=10) | Colon adenoma (n=5) | -1.0  | 0.370   | 1.6   | 0.990   | -2.1  | <0.001  | (53) |
| Normal colon epithelium (n=10) | Colorectal adenoma epithelium (n=5) | -1.2  | 0.050   | 1.2   | 0.940   | -1.7  | 0.005   | (53) |

Fold-change in mRNA expression in adenomas relative to adjacent normal tissue (number of tissue samples evaluated in parentheses). Source, www.oncomine.com.
inflammatory bowel disease, a known CRC risk factor (60). The mechanism whereby PER3 may exert a tumor suppressor function is currently unknown. The clock genes exert genetic and epigenetic regulatory effects that facilitate the circadian expression of ~5-10% of the entire mammalian transcriptome (6-10), including other known tumor suppressors and oncogenes (e.g., c-Myc, p53) (31,61,62). Clock genes also help regulate cellular processes that are active during carcinogenesis (cell proliferation, DNA damage response, apoptosis), and clock gene dysregulation may foster adenoma formation by influencing these pathways (4,11,13,15).

Individuals with the 5-repeat PER3 VNTR sequence tend to have relatively penetrant phenotypic characteristics including delayed sleep phase syndrome, increased susceptibility to cognitive impairment after sleep deprivation, morning circadian preference and differences in the timing or levels of circadian hormone secretion (16,37,40), although some inconsistencies have been reported (21,39,63-65). Whether alterations in sleep and other circadian processes can increase cancer susceptibility remains to be determined, although studies of shift work and cancer incidence suggest this is possible (3,4,24). In the present study, participants with the 5-repeat allele reported less cumulative shift work experience relative to those with the 4/4 genotype (Table III). Additional research is needed to determine whether this is a chance finding or if individuals carrying these variants are less tolerant of shift work and self-select out of these occupations relative to those with the 4/4 genotype. Individuals with the 5-repeat allele may be more susceptible to disturbances in circadian timekeeping (16,37,40,41). For example, those carrying the 5/5 PER3 variant were sensitive to light-induced melatonin suppression whereas 4/4 homozygotes were not responsive (41). Since melatonin has potent antioxidant, antiproliferative and anti-inflammatory properties in the gastrointestinal tract, a reduction in its secretion (e.g., by exposure to light at night) may facilitate physiologic changes that predispose to increased risks for CRC or other cancers (3,4,20,22,23). Although PER3 has tumor suppressor properties and its length polymorphism tends to have relatively penetrant phenotypic characteristics, the role of these factors in cancer susceptibility, if any, remains to be characterized.

In conclusion, the present study indicates that individuals with the 5-repeat PER3 length polymorphism may be more susceptible to adenoma formation. The results are consistent with Oncomine data indicating that PERIOD clock gene expression is reduced in adenomas relative to normal GI tissue. Further interrogation of interrelationships between the PER3 VNTR and genetic or epigenetic pathways that may facilitate adenoma risk, such as changes in the expression of clock-controlled, cancer-related genes, is recommended. Further elucidation of the PER3 VNTR genotype in relation to circadian rhythm or clock gene dysregulation may lead to development of novel, modifiable targets for adenoma and CRC prevention.

Acknowledgements

The authors declare that there are no conflicts of interest. This study was supported by a supplemental grant from the National Cancer Institute (NCI) as part of the South Carolina Cancer Disparities Community Network (3 U01 CA114601-03S5, PI, J.R. Hébert; Co-Project Leaders: J.B. Burch and S.E. Steck), and by the parent grant, South Carolina Cancer Disparities Community Network [U01 CA114601 Hebert, J.R. (PI)]. Dr J.B. Burch was supported by a Career Development Award from the USA Department of Veterans Affairs, VISN-7, Charleston, SC, and the Arnold School of Public Health and Center for Colorectal Cancer Research, University of South Carolina, Columbia, SC, USA. Melanie Alexander was supported by the University of South Carolina Behavioral-Biomedical Interface Program, funded in part by training grant T32-5R18CE001240 from the National Institute of General Medical Sciences. Dr J.R. Hébert was supported by an Established Investigator Award in Cancer Prevention and Control from the Cancer Training Branch of NCI (K05 CA136975). Dr S.E. Steck was supported by a University of South Carolina Research Opportunity Award and by the USC Center for Colon Cancer Research (COBRE 5P20RR017698). The South Carolina Medical Endoscopy Center (SCMEC) and the William Jennings Bryant Dorn Veterans Administration Medical Center (DVAMC) served as recruitment sites and provided additional research support. The authors thank Matt Darmer at the Greenwood Genetic Center for providing technical assistance with PCR and Sanger sequencing.

References

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Conteduca V, Sansonno D, Russi S and Dammacco F: Pecanoceruous colorectal lesions (Review). Int J Oncol 43: 973-984, 2013.
3. Haus EL and Smolensky MH: Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev 17: 273-284, 2013.
4. Lahiri T, Merikanto I and Partonen T: Circadian clock disruptions and the risk of cancer. Ann Med 44: 847-853, 2012.
5. Landgraf D, Shostak A and Oster H: Clock genes and sleep. Pflugers Archiv 463: 3-14, 2012.
6. Masri S, Zocchi L, Katada S, Mora E and Sassone-Corsi P: The circadian clock transcriptional complex: metabolic feedback intersects with epigenetic control. Ann NY Acad Sci 1264: 103-109, 2012.
7. Panda S, Antoch MP, Miller BH, et al.: Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 109: 307-320, 2002.
8. Schibler U: The daily timing of gene expression and physiology in mammals. Dialogues Clin Neurosci 9: 257-272, 2007.
9. Ripperger JA and Merrow M: Perfect timing: epigenetic regulation of the circadian clock. FEBS Lett 585: 1406-1411, 2011.
10. Storch KF, Lipan O, Leykin I, et al.: Extensive and divergent circadian gene expression in liver and heart. Nature 417: 78-83, 2002.
11. Wood P, Yang X and Hrushefsky W: The role of circadian rhythm in carcinogenesis of colorectal cancer. Curr Colorectal Cancer Rep 6: 74-81, 2010.
12. Kang TH and Sancar A: Circadian regulation of DNA excision repair: implications for chrono-chemotherapy. Cell Cycle 8: 1665-1667, 2009.
13. Yu EA and Weaver DR: Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging 3: 479-493, 2011.
14. Yang MY, Yang WC, Lin PM, et al.: Altered expression of circadian clock genes in human chronic myeloid leukemia. J Biol Rhythms 26: 136-148, 2011.
15. Chen-Goodspeed M and Lee CC: Tumor suppression and circadian function. J Biol Rhythms 22: 291-298, 2007.
16. Dijk DJ and Archer SN: PERIOD3, circadian phenotypes, and sleep homeostasis. Sleep Med Rev 14: 151-160, 2010.
17. Ebisawa T: Analysis of the molecular pathophysiology of sleep disorders relevant to a disturbed biological clock. Mol Genet Genomics 288: 185-193, 2013.
18. Thompson CL, Larkin EK, Patel S, Berger NA, Redline S and Li L: Short duration of sleep increases risk of colorectal adenoma. Cancer 117: 841-847, 2011.

19. Burch JB, Mithal A and Sun Y: Disruption of circadian rhythms and sleep: role in carcinogenesis. In: The Encyclopedia of Sleep, Kushida CA (ed). Vol 3. Academic Press, Waltham, MA, pp.150-155, 2013.

20. Jiao L, Duan Z, Sangi-Haghpeykar H, Hale L, White DL and El-Serag HB: Sleep duration and incidence of colorectal cancer in postmenopausal women. Br J Cancer 108: 213-221, 2013.

21. Wirth MD, Burch JB, Hébert JR, et al: Case-control study of breast cancer in India: Role of PERIOD3 clock gene length polymorphism and chromosome. Cancer Invest 32: 329-329, 2014.

22. Schilling S, Lauterbach F, Speitger FE, et al: Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 95: 825-828, 2003.

23. Parent ME, El-Zein M, Rousseau MC, Pintos J and Siemiatycki J: Night work and the risk of cancer among men. Am J Epidemiol 176: 751-759, 2012.

24. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Painting, Firefighting and Shiftwork. International Agency for Research on Cancer. World Health Organization. Vol 98. Lyon, France, 2007.

25. Scheiermann C, Kunisaki Y and Frenette PS: Circadian control of the immune system. Nat Rev Immunol 13: 190-198, 2013.

26. Arjona A, Silver AC, Walker W E and Fikrig E: Immunity's fourth dimension: approaching the circadian-immune connection. Trends Immunol 33: 607-612, 2012.

27. Climent J, Perez-Losada J, Quigley DA, et al: Association study of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol 28: 3770-3778, 2010.

28. Neumann O, Kesselmeier M, Güssler R, et al: Methylohexane analysis and circadian gene expression of human HCCs identify novel protumorigenic factors. Hepatology 56: 1817-1827, 2012.

29. Cao Q, Gery S, Dashti A, et al: Analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology 56: 1817-1827, 2012.

30. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D and Koeffler HP: Disruption of circadian rhythms and sleep: role in carcinogenesis. In: The Encyclopedia of Sleep, Kushida CA (ed). Vol 3. Academic Press, Waltham, MA, pp.150-155, 2013.

31. Li L: Short duration of sleep increases risk of colorectal adenoma. Cancer 117: 841-847, 2011.

32. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D and Koeffler HP: Disruption of circadian rhythms and sleep: role in carcinogenesis. In: The Encyclopedia of Sleep, Kushida CA (ed). Vol 3. Academic Press, Waltham, MA, pp.150-155, 2013.

33. Zhu Y, Brown hN, Zhang Y, Stevens RG and Zheng T: Association of the clock gene PER3 and ARNTL with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 141B: 234-241, 2006.

34. Arjona A, Silver AC, Walker W E and Fikrig E: Immunity's fourth dimension: approaching the circadian-immune connection. Trends Immunol 33: 607-612, 2012.

35. Burch JB, Wirth MD, Hébert JR, et al: Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 95: 825-828, 2003.

36. Parent ME, El-Zein M, Rousseau MC, Pintos J and Siemiatycki J: Night work and the risk of cancer among men. Am J Epidemiol 176: 751-759, 2012.

37. Barbosa AA, Pedrazzolli M, Koike BD and Tufik S: Do Caucasian and Asian Clocks Tick Differently? Braz J Med Biol Res 43: 96-99, 2010.

38. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D and Koeffler HP: Disruption of circadian rhythms and sleep: role in carcinogenesis. In: The Encyclopedia of Sleep, Kushida CA (ed). Vol 3. Academic Press, Waltham, MA, pp.150-155, 2013.

39. Mazzoccoli G, Panza A, Valvano MR, et al: Immunity's fourth dimension: approaching the circadian-immune connection. Trends Immunol 33: 607-612, 2012.

40. Viola AU, Chellappa SL, Archer SN, et al: Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Mol Carcinog 48: 642-647, 2009.

41. Wirth M, Burch J, Violanti J, et al: Association of the Period3 clock gene length polymorphism with salivary cortisol secretion among police officers. Neuro Endocrinol Lett 34: 27-37, 2013.

42. Lázár ÁS, Slak A, Lo JC, et al: Sleep, diurnal preference, health, and psychological well-being: a prospective single-alleleic-variation study. Chronobiol Int 29: 131-146, 2012.

43. Pereira DS, Tufik S, Louzada FM, et al: Association of the length polymorphism in the circadian clock gene Per1 with the delayed sleep-phase syndrome: does latitude have an influence upon it? Sleep 29: 29-32, 2005.

44. Gery S and Koeffler HP: Circadian rhythms and cancer. Cell Cycle 9: 1097-1103, 2010.

45. Tomlinson IP, Dunlop M, Campbell H, et al: COGENT (COlorectal cancer GENEtics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer. Br J Cancer 102: 447-454, 2010.

46. Mazzoccoli G, Palmieri O, Corritore G, et al: Association study of a polymorphism in clock gene PERIOD3 and risk of inflammatory bowel disease. Chronobiol Int 29: 994-1003, 2012.

47. Lee CC: The circadian clock and tumor suppression by mammalian period genes. Methods Enzymol 393: 852-861, 2005.

48. Gery S and Koeffler HP: Circadian rhythms and cancer. Cell Cycle 9: 1097-1103, 2010.

49. Olstad TM, Bjorvatn BR, Steen VM and Pallesen S: Association study of a variable-number tandem repeat polymorphism in the clock gene PERIOD3 and chronic fatigue syndrome in postmenopausal women. Chronobiol Int 28: 764-770, 2011.